Hanx Biopharmaceuticals repurchases 22,800 H-shares for HKD 0.63 million, lifting treasury stock to 1.54 million

Bulletin Express06-24

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 24 June 2026 it bought back 22,800 H-shares on the Hong Kong Stock Exchange at prices between HKD 26.90 and HKD 28.10, for a total consideration of HKD 0.63 million. The volume-weighted average buyback price was HKD 27.63 per share.

Following the transaction, issued shares outstanding (excluding treasury shares) declined by 0.017% to 134.67 million, while treasury shares rose to 1.54 million. Total issued share count remained unchanged at 136.22 million.

The repurchase utilised 22,800 shares, equivalent to 0.0169% of the 13.47 million shares authorised under the shareholder mandate granted on 24 June 2026. Under Main Board Rule 10.06(3)(a), the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, extending to 24 July 2026.

Management confirmed that the repurchase was conducted in accordance with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125021599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125021599","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals repurchases 22,800 H-shares for HKD 0.63 million, lifting treasury stock to 1.54 million","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 24 June 2026 it bought back 22,800 H-shares on the Hong Kong Stock Exchange at prices between HKD 26.90 and HKD 28.10, for a total consideration of HKD 0.63 million. The volume-weighted average buyback price was HKD 27.63 per share.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury shares) declined by 0.017% to 134.67 million, while treasury shares rose to 1.54 million. Total issued share count remained unchanged at 136.22 million.</p>\n<p>The repurchase utilised 22,800 shares, equivalent to 0.0169% of the 13.47 million shares authorised under the shareholder mandate granted on 24 June 2026. Under Main Board Rule 10.06(3)(a), the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, extending to 24 July 2026.</p>\n<p>Management confirmed that the repurchase was conducted in accordance with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals repurchases 22,800 H-shares for HKD 0.63 million, lifting treasury stock to 1.54 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals repurchases 22,800 H-shares for HKD 0.63 million, lifting treasury stock to 1.54 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-24 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 24 June 2026 it bought back 22,800 H-shares on the Hong Kong Stock Exchange at prices between HKD 26.90 and HKD 28.10, for a total consideration of HKD 0.63 million. The volume-weighted average buyback price was HKD 27.63 per share.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury shares) declined by 0.017% to 134.67 million, while treasury shares rose to 1.54 million. Total issued share count remained unchanged at 136.22 million.</p>\n<p>The repurchase utilised 22,800 shares, equivalent to 0.0169% of the 13.47 million shares authorised under the shareholder mandate granted on 24 June 2026. Under Main Board Rule 10.06(3)(a), the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, extending to 24 July 2026.</p>\n<p>Management confirmed that the repurchase was conducted in accordance with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1125021599","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125021599","pubTimestamp":1782309951,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 24 June 2026 it bought back 22,800 H-shares on the Hong Kong Stock Exchange at prices between HKD 26.90 and HKD 28.10, for a total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"Hanx Biopharmaceuticals以63万港元回购2.28万股H股，库存股增至154万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 24 June 2026 it bought back 22,800 H-shares on the Hong Kong Stock Exchange at prices between HKD 26.90 and HKD 28.10, for a total consideration of HKD 0.63 million. The volume-weighted average buyback price was HKD 27.63 per share.\nFollowing the transaction, issued shares outstanding (excluding treasury shares) declined by 0.017% to 134.67 million, while treasury shares rose to 1.54 million. Total issued share count remained unchanged at 136.22 million.\nThe repurchase utilised 22,800 shares, equivalent to 0.0169% of the 13.47 million shares authorised under the shareholder mandate granted on 24 June 2026. Under Main Board Rule 10.06(3)(a), the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, extending to 24 July 2026.\nManagement confirmed that the repurchase was conducted in accordance with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125021599","isCrawlerRequest":true}